Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Hepatitis

  Free Subscription


14.10.2019

1 Arch Virol
2 Clin Infect Dis
1 Eur J Gastroenterol Hepatol
1 Gastroenterol Hepatol
1 Gastroenterology
2 Hepatology
5 J Hepatol
2 J Med Virol
2 J Viral Hepat
1 J Virol
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Arch Virol

  1. RYLL R, Heckel G, Corman VM, Drexler JF, et al
    Genomic and spatial variability of a European common vole hepevirus.
    Arch Virol. 2019;164:2671-2682.
    PubMed     Text format     Abstract available


    Clin Infect Dis

  2. LY KN, Minino AM, Liu SJ, Roberts H, et al
    Deaths Associated with Hepatitis C Virus Infection among Residents in 50 States and the District of Columbia, 2016-2017.
    Clin Infect Dis. 2019 Oct 5. pii: 5581721. doi: 10.1093.
    PubMed     Text format     Abstract available

  3. MARTINELLO M, Yee J, Bartlett SR, Read P, et al
    Moving towards hepatitis C micro-elimination among people living with HIV in Australia: the CEASE study.
    Clin Infect Dis. 2019 Oct 4. pii: 5581531. doi: 10.1093.
    PubMed     Text format     Abstract available


    Eur J Gastroenterol Hepatol

  4. WIEGAND J, Buggisch P, Mauss S, Boeker KHW, et al
    Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
    Eur J Gastroenterol Hepatol. 2019;31:1424-1431.
    PubMed     Text format     Abstract available


    Gastroenterol Hepatol

  5. CRESPO J, Albillos A, Buti M, Calleja JL, et al
    Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH).
    Gastroenterol Hepatol. 2019 Oct 5. pii: S0210-5705(19)30208.
    PubMed     Text format     Abstract available


    Gastroenterology

  6. VERRIER ER, Majzoub K, Baumert TF
    Hepatitis D Virus Infection Revisited.
    Gastroenterology. 2019 Oct 3. pii: S0016-5085(19)41373.
    PubMed     Text format    


    Hepatology

  7. LI J, Cheung RC, Nguyen MH
    Chronic hepatitis B and NASH: Is "fat" all bad?
    Hepatology. 2019 Oct 8. doi: 10.1002/hep.30983.
    PubMed     Text format     Abstract available

  8. HUANG R, Wang J, Zhang Z, Yan X, et al
    Letter to the Editor: Impact of non-alcoholic steatohepatitis on liver-related outcomes in chronic hepatitis B.
    Hepatology. 2019 Oct 6. doi: 10.1002/hep.30981.
    PubMed     Text format     Abstract available


    J Hepatol

  9. CHEN HL, Ni YH, Chen PJ, Chang MH, et al
    Antiviral treatment for hepatitis B in infancy: Still an issue for debate.
    J Hepatol. 2019 Sep 30. pii: S0168-8278(19)30465.
    PubMed     Text format    

  10. DESAI R, Singh S, Zalavadia D, Bansal P, et al
    Burden of hepatitis E infection and associated healthcare resource utilization among hematological malignancy-related hospitalizations: A national perspective in the United States, 2007-2014.
    J Hepatol. 2019 Sep 30. pii: S0168-8278(19)30523.
    PubMed     Text format    

  11. VRANCKEN B, Cuypers L, Perez AB, Chueca N, et al
    Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes.
    J Hepatol. 2019 Oct 1. pii: S0168-8278(19)30476.
    PubMed     Text format    

  12. VON FELDEN J, Mallet V, Pischke S
    Reply to: "Burden of hepatitis E infection and associated healthcare resource utilization among hematological malignancy-related hospitalizations: A national perspective in the United States, 2007-2014".
    J Hepatol. 2019 Oct 1. pii: S0168-8278(19)30532.
    PubMed     Text format    

  13. LEE JH, Kim KH
    Reply to: "In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients."
    J Hepatol. 2019 Oct 1. pii: S0168-8278(19)30524.
    PubMed     Text format    


    J Med Virol

  14. TSAI TC, Deng ST, Hsu CW
    The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan.
    J Med Virol. 2019 Oct 10. doi: 10.1002/jmv.25605.
    PubMed     Text format     Abstract available

  15. SAITO Y, Imamura M, Uchida T, Osawa M, et al
    Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
    J Med Virol. 2019 Oct 4. doi: 10.1002/jmv.25602.
    PubMed     Text format     Abstract available


    J Viral Hepat

  16. RUSSO FP, Zanetto A, Gambato M, Bortoluzzi I, et al
    Hepatitis C virus eradication with direct acting antiviral improves insulin resistance.
    J Viral Hepat. 2019 Oct 9. doi: 10.1111/jvh.13215.
    PubMed     Text format     Abstract available

  17. ZENG Y, Chen S, Fu Y, Wu W, et al
    Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
    J Viral Hepat. 2019 Oct 10. doi: 10.1111/jvh.13216.
    PubMed     Text format     Abstract available


    J Virol

  18. WU MJ, Shanmugam S, Welsch C, Yi M, et al
    Palmitoylation of the hepatitis C virus NS2 regulates its subcellular localization and NS2-NS3 autocleavage.
    J Virol. 2019 Oct 9. pii: JVI.00906-19. doi: 10.1128/JVI.00906.
    PubMed     Text format     Abstract available


    PLoS One

  19. GARCIA A, Moore Boffi S, Gayet-Ageron A, Vernaz N, et al
    Access to unauthorized hepatitis C generics: Perception and knowledge of physicians, pharmacists, patients and non-healthcare professionals.
    PLoS One. 2019;14:e0223649.
    PubMed     Text format     Abstract available

  20. RAYAN DA'AS S, Azzeh M
    Subgenotyping and genetic variability of hepatitis C virus in Palestine.
    PLoS One. 2019;14:e0222799.
    PubMed     Text format     Abstract available

  21. MA TL, Hu TH, Hung CH, Wang JH, et al
    Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.
    PLoS One. 2019;14:e0222221.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: